EHP-101 is an oral formulation of a new chemical entity derived from synthetic cannabidiol, also known as CBD, one of the most abundant molecules found in the cannabis plant. The fully synthetic novel molecule formulated in EHP-101 has been rationally designed to enhance the therapeutic benefits of CBD by being a dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid type 2 receptor (CB2) agonist that also activates the hypoxia inducible factor (HIF) pathway. PPARγ and CB2 are preclinically validated therapeutic targets, supported by scientific literature, for the development of novel drugs modulating inflammatory responses for the treatment of multiple sclerosis (MS) as well as for the treatment of systemic sclerosis, a form of scleroderma (SSc). In addition, EHP-101 is an activator of the hypoxia-inducible factor (HIF) pathway, which may have additional benefits to MS and SSc patients, as the HIF pathway modulates the immune response that favors both neuroprotection and myelin regeneration in MS as well as prevents collagen deposition around blood vessels and reduces vascular damage in SSc.
Furthermore, evidence shows these validated receptors may be beneficial in preventing neuroinflammation and demyelination in the CNS, and fibrogenesis in the periphery. Based on these activities, EHP is initially developing this proprietary new drug candidate for multiple sclerosis and systemic sclerosis (scleroderma).